Literature DB >> 27612480

Signatures of prostate-derived Ets factor (PDEF) in cancer.

Nitin Mahajan1.   

Abstract

The Ets proteins are a family of transcription factors characterized by an evolutionarily conserved DNA-binding domain and have diverse biological functions including tumor suppressor as well as tumor promoter functions. They are regulated via a complex and diverse number of mechanisms and control key cellular processes. Prostate-derived Ets transcription factor (PDEF), a unique member of the ETS family, is present in tissues with high epithelial content are hormone-regulated, such as prostate, breast, salivary glands, ovaries, colon, airways, and stomach tissues. PDEF (prostate-derived Ets factor) is also referred to as SPDEF (SAM pointed domain containing Ets transcription factor), PSE (mouse homolog), or hPSE (human PSE) in the literature and is the sole member of the PDEF ETS sub-family. The role of PDEF in cancer development is still not fully elucidated though. The present article focuses on the key findings about the PDEF's biological functions, interacting proteins, and its target genes. There is a strong urge to focus on the clinical studies in larger cohort, which elucidate the regulation of PDEF and its target genes, to determine the potential of PDEF as biomarker. Based on the studies discussed in the present article, one can anticipate that PDEF offers a great potential for developing therapeutics against cancer.

Entities:  

Keywords:  Cancer; PDEF; PSE; SPDEF; Tumor suppressor

Mesh:

Substances:

Year:  2016        PMID: 27612480     DOI: 10.1007/s13277-016-5326-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  39 in total

Review 1.  The ETS-domain transcription factor family.

Authors:  A D Sharrocks
Journal:  Nat Rev Mol Cell Biol       Date:  2001-11       Impact factor: 94.444

2.  Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).

Authors:  A Krüger; R Soeltl; V Lutz; O G Wilhelm; V Magdolen; E E Rojo; P A Hantzopoulos; H Graeff; B Gänsbacher; M Schmitt
Journal:  Cancer Gene Ther       Date:  2000-02       Impact factor: 5.987

3.  Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression.

Authors:  David P Turner; Victoria J Findlay; Omar Moussa; Victor I Semenchenko; Patricia M Watson; Amanda C LaRue; Mohamed M Desouki; Mostafa Fraig; Dennis K Watson
Journal:  Prostate       Date:  2011-03-28       Impact factor: 4.104

4.  Profile of Ets gene expression in human breast carcinoma.

Authors:  Jin He; Yong Pan; Jianhua Hu; Constance Albarracin; Yun Wu; Jia Le Dai
Journal:  Cancer Biol Ther       Date:  2007-01       Impact factor: 4.742

5.  Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.

Authors:  Luciane Rostirola Cavazzola; Gustavo Franco Carvalhal; Candida Deves; Daiana Renck; Ricardo Almeida; DIóGENES Santiago Santos
Journal:  Oncol Lett       Date:  2015-04-01       Impact factor: 2.967

6.  Novel role for PDEF in epithelial cell migration and invasion.

Authors:  Ruwanthi N Gunawardane; Dennis C Sgroi; Carolyn N Wrobel; Eugene Koh; George Q Daley; Joan S Brugge
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

7.  Requirement of the epithelium-specific Ets transcription factor Spdef for mucous gland cell function in the gastric antrum.

Authors:  David Horst; Xuesong Gu; Manoj Bhasin; Quanli Yang; Michael Verzi; Dongxu Lin; Marie Joseph; Xiaobo Zhang; Wei Chen; Yi-Ping Li; Ramesh A Shivdasani; Towia A Libermann
Journal:  J Biol Chem       Date:  2010-08-26       Impact factor: 5.157

8.  Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression.

Authors:  Jeremy S Schaefer; Yamini Sabherwal; Heidi Y Shi; Venkataraman Sriraman; JoAnne Richards; Alex Minella; David P Turner; Dennis K Watson; Ming Zhang
Journal:  J Biol Chem       Date:  2010-02-05       Impact factor: 5.157

9.  Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer.

Authors:  J J Frietsch; T G P Grunewald; S Jasper; U Kammerer; S Herterich; M Kapp; A Honig; E Butt
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

10.  Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression.

Authors:  Sejin Kim; Joungho Han; Jhingook Kim; Chaehwa Park
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

View more
  2 in total

1.  AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.

Authors:  Lu Cao; Cong Xu; Guomin Xiang; Fang Liu; Xiaozhen Liu; Congying Li; Jing Liu; Qingxiang Meng; Jiao Jiao; Yun Niu
Journal:  Mol Cancer       Date:  2018-09-14       Impact factor: 27.401

2.  Combined Transcriptome and Proteome Analysis of Immortalized Human Keratinocytes Expressing Human Papillomavirus 16 (HPV16) Oncogenes Reveals Novel Key Factors and Networks in HPV-Induced Carcinogenesis.

Authors:  Frank Rösl; Martina Niebler; Ruwen Yang; Jana Klimentová; Elke Göckel-Krzikalla; Regina Ly; Nadine Gmelin; Agnes Hotz-Wagenblatt; Helena Řehulková; Jiří Stulík
Journal:  mSphere       Date:  2019-03-27       Impact factor: 4.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.